Literature DB >> 980079

Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

S H Polmar, R C Stern, A L Schwartz, E M Wetzler, P A Chase, R Hirschhorn.   

Abstract

To evaluate their role as a form of replacement therapy, frozen irradiated red blood cells were administered to a child with adenosine deaminase deficiency associated with severe combined immunodeficiency disease. In vitro lymphocyte responses to mitogens and allogeneic cells were restored. Subsequently, a "thymus shadow" appeared, and immunoglobulin synthesis was demonstrated. Frozen irradiated plasma, which alone had no effect on lymphocytes numbers or responses, promoted lymphocytosis when given with frozen irradiated red blood cells. The patient received the transfusions with or without irradiated plasma at four-week intervals and remained free of infection for 17 months. The patient's lymphocyte adenosine triphosphate levels were elevated before therapy, which consistently reduced them without altering the lymphocyte adenosine deaminase activity. Enzyme replacement therapy may provide a way to treat patients with adenosine deaminase deficiency associated with severe combined immunodeficiency disease who do not have histocompatible bone-marrow donors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 980079     DOI: 10.1056/NEJM197612092952402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  43 in total

Review 1.  How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).

Authors:  Donald B Kohn; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2017-02-14       Impact factor: 8.317

Review 2.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

3.  Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.

Authors:  J Donofrio; M S Coleman; J J Hutton; A Daoud; B Lampkin; J Dyminski
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

4.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity.

Authors:  T S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

5.  In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients.

Authors:  M S Hershfield; N M Kredich; D R Ownby; H Ownby; R Buckley
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

6.  Prenatal diagnosis for adenosine deaminase deficiency.

Authors:  J B Ziegler; M B Van der Weyden; C H Lee; A Daniel
Journal:  J Med Genet       Date:  1981-04       Impact factor: 6.318

7.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

Review 8.  Metabolic defects in immunodeficiency diseases.

Authors:  A D Webster
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  In vitro of adenosine on lymphocytes and erythrocytes from horses with combined immunodeficiency.

Authors:  N S Magnuson; L E Perryman
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.